Cerus (NASDAQ:CERS) Releases Quarterly Earnings Results, Meets Expectations

Cerus (NASDAQ:CERS) announced its earnings results on Thursday. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01), FiscalAI reports. The business had revenue of $63.30 million for the quarter, compared to the consensus estimate of $62.90 million. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%.

Here are the key takeaways from Cerus’ conference call:

• Q2 product revenue rose 10% to $57.4 million, while first-half revenue increased 16% year over year. Cerus raised the low end of its 2026 product revenue guidance to $229 million–$231 million, implying 11%–12% annual growth.
• INTERCEPT fibrinogen complex (IFC) revenue grew approximately 40% excluding prior-period revenue, with demand up 43%; Cerus raised its 2026 IFC revenue outlook to $23 million–$25 million. The company cited growing hospital adoption, BCA collaboration, and the product’s immediate availability and five-day post-thaw shelf life.
• Cerus refinanced its debt, reducing the term loan by $30 million and expecting to lower annual interest expense by up to $3.5 million. Adjusted EBITDA remained positive for the ninth consecutive quarter, and management said it has a path toward GAAP profitability.
• Product gross margin declined to 51.4% from 55.2% a year earlier due to currency and inflationary pressures; management expects full-year 2026 margins to remain in the low 50% range. Operating cash flow was negative $2.7 million, primarily because of higher inventory supporting expected growth.
• The company submitted its INT200 platelet PMA to the FDA and could receive approval as early as the first half of 2027. Cerus also expects Phase III INTERCEPT red blood cell trial results in the fourth quarter and expanded its BARDA contract by nearly $22 million to support U.S. regulatory activities.

Cerus Stock Up 0.7%

CERS stock traded up $0.02 during midday trading on Thursday, hitting $2.89. 1,935,522 shares of the company’s stock were exchanged, compared to its average volume of 2,129,708. The firm has a 50 day moving average price of $2.87 and a 200-day moving average price of $2.43. Cerus has a 12-month low of $1.15 and a 12-month high of $3.47. The stock has a market capitalization of $579.07 million, a price-to-earnings ratio of -57.80 and a beta of 1.77. The company has a current ratio of 1.63, a quick ratio of 1.06 and a debt-to-equity ratio of 0.47.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CERS. Wall Street Zen raised shares of Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Zacks Research raised shares of Cerus from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 30th. BTIG Research upgraded shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Friday, May 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cerus in a report on Thursday, June 18th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.00.

Insider Activity at Cerus

In related news, insider Chrystal Jensen sold 24,329 shares of Cerus stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $2.94, for a total value of $71,527.26. Following the completion of the sale, the insider owned 966,657 shares in the company, valued at approximately $2,841,971.58. The trade was a 2.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Eric Bjerkholt sold 20,454 shares of the company’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $2.60, for a total transaction of $53,180.40. Following the completion of the sale, the director directly owned 261,679 shares in the company, valued at $680,365.40. This represents a 7.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 256,071 shares of company stock worth $747,894. 5.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cerus

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Cerus by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock valued at $17,147,000 after purchasing an additional 62,663 shares in the last quarter. Wasatch Advisors LP increased its holdings in Cerus by 2.6% in the second quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock valued at $12,033,000 after buying an additional 213,917 shares during the last quarter. Millennium Management LLC raised its stake in Cerus by 17.6% during the third quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock valued at $5,517,000 after buying an additional 519,301 shares in the last quarter. Ieq Capital LLC grew its position in shares of Cerus by 1.1% in the 4th quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company’s stock worth $4,993,000 after acquiring an additional 25,771 shares in the last quarter. Finally, AQR Capital Management LLC grew its position in shares of Cerus by 291.6% in the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock worth $1,986,000 after acquiring an additional 1,064,133 shares in the last quarter. Institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.